Clinical trial
A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
NCT00445978 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00445978 |
|---|---|
| Title | A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease |
| Official title | A Phase 2a, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Efficacy of 6R-BH4 in Subjects With Sickle Cell Disease |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | Sapropterin Dihydrochloride |
| Enrollment | 32 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Mar 9, 2007 |
| Last update posted | Feb 25, 2021 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: